Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor
Circulation · 11.07.2023 · 148 (2) · 144-158
DOI: 10.1161/circulationaha.122.063372 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 11.07.2023. Verfasst von Douglas G Johns und 40 weiteren Autor:innen. Beteiligte Einrichtung: MRL, Merck & Co., Inc., Rahway, NJ (D.G.J., L.-C.C., P.B., A.B., T.B., P.G.B., I.C., F.-X.D., R.M.G., E.D.G., Y.G., S.N.H., J.M.J., H.J., E.A.K., K.A…. Hauptthemen laut MEDLINE: Anticholesteremic Agents, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypercholesterolemia. Die Arbeit wurde bisher 179-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9)-low density lipoprotein receptor interaction with injectable monoclonal antibodies or small interfering RNA lowers plasma low density lipoprotein-cholesterol, but despite nearly 2 decades of effort, an oral inhibitor of PCSK9 is not available. Macrocyclic peptides represent a novel approach to target proteins traditionally considered intractable to small-molecule drug design.
Methods
Novel mRNA display screening technology was used to identify lead chemical matter, which was then optimized by applying structure-based drug design enabled by novel synthetic chemistry to identify macrocyclic peptide (MK-0616) with exquisite potency and selectivity for PCSK9. Following completion of nonclinical safety studies, MK-0616 was administered to healthy adult participants in a single rising-dose Phase 1 clinical trial designed to evaluate its safety, pharmacokinetics, and pharmacodynamics. In a multiple-dose trial in participants taking statins, MK-0616 was administered once daily for 14 days to characterize the safety, pharmacokinetics, and pharmacodynamics (change in low density lipoprotein cholesterol).
Results
MK-0616 displayed high affinity ( K i = 5pM) for PCSK9 in vitro and sufficient safety and oral bioavailability preclinically to enable advancement into the clinic. In Phase 1 clinical studies in healthy adults, single oral doses of MK-0616 were associated with >93% geometric mean reduction (95% CI, 84–103) of free, unbound plasma PCSK9; in participants on statin therapy, multiple–oral-dose regimens provided a maximum 61% geometric mean reduction (95% CI, 43–85) in low density lipoprotein cholesterol from baseline after 14 days of once-daily dosing of 20 mg MK-0616.
Conclusions
This work validates the use of mRNA display technology for identification of novel oral therapeutic agents, exemplified by the identification of an oral PCSK9 inhibitor, which has the potential to be a highly effective cholesterol lowering therapy for patients in need.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MRL, Merck & Co., Inc., Rahway, NJ (D.G.J., L.-C.C., P.B., A.B., T.B., P.G.B., I.C., F.-X.D., R.M.G., E.D.G., Y.G., S.N.H., J.M.J., H.J., E.A.K., K.A.K., J.T.K., E.L., C.L.L., A.Y.H.L., L.L., A.G.N., E.A.O., S.A.S., D.A…
- Peptide & Small Molecules R&D, IRBM S.p.A., Pomezia (RM), Italy (E.B., D.B.).
- Now with Cayman Chemical Company, Ann Arbor, MI (E.D.G.).
- Clinical Pharmacology Unit, SGS Life Sciences, Antwerp, Belgium (F.P.V., B.V.).
ORCID-Profile: Douglas G Johns, Louis-Charles Campeau, Puja Banka, Tjerk Bueters, Elisabetta Bianchi, Danila Branca, Robert M Garbaccio, Hubert Josien, Kenneth A Koeplinger, Jeffrey T Kuethe, Eseng Lai, S Aubrey Stoch, David A Thaisrivongs, Thomas J Tucker, Petr Vachal, Bram Volckaert, Abbas M Walji, Harold B Wood
Zitieren
APA
Johns, D. G., Campeau, L. C., Banka, P., Bautmans, A., Bueters, T., Bianchi, E., Branca, D., Bulger, P. G., Crevecoeur, I., Ding, F. X., Garbaccio, R. M., Guetschow, E. D., Guo, Y., Ha, S. N., Johnston, J. M., Josien, H., Kauh, E. A., Koeplinger, K. A., Kuethe, J. T., …, & Wood, H. B. (2023). Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor. Circulation, 148(2), 144-158. https://doi.org/10.1161/circulationaha.122.063372
Vancouver
Johns DG, Campeau LC, Banka P, Bautmans A, Bueters T, Bianchi E, et al. Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor. Circulation. 2023;148(2):144-158. doi:10.1161/circulationaha.122.063372
BibTeX
@article{Johns2023,
author = {Johns, Douglas G and Campeau, Louis-Charles and Banka, Puja and Bautmans, An and Bueters, Tjerk and Bianchi, Elisabetta and Branca, Danila and Bulger, Paul G and Crevecoeur, Inne and Ding, Fa-Xiang and Garbaccio, Robert M and Guetschow, Erik D and Guo, Yan and Ha, Sookhee N and Johnston, Jennifer M and Josien, Hubert and Kauh, Eunkyung A and Koeplinger, Kenneth A and Kuethe, Jeffrey T and Lai, Eseng and Lanning, Christine L and Lee, Anita Y H and Li, Li and Nair, Anilkumar G and O'Neill, Edward A and Stoch, S Aubrey and Thaisrivongs, David A and Tucker, Thomas J and Vachal, Petr and van Dyck, Kristien and Vanhoutte, Frederic P and Volckaert, Bram and Wolford, Dennis G and Xu, Andy and Zhao, Tian and Zhou, Dan and Zhou, Susan and Zhu, Xiaohong and Zokian, Hratch J and Walji, Abbas M and Wood, Harold B},
title = {Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor},
journal = {Circulation},
year = {2023},
volume = {148},
number = {2},
pages = {144--158},
doi = {10.1161/circulationaha.122.063372}
}
EUVIMED